Since NSCLC patients with epidermal growth factor receptor (EGFR)-activating mutations (exon 19 deletion and exon 21 L858R mutation), which are observed in 20–40% of Asian patients, demonstrated high response to EGFR tyrosine kinase inhibitors (TKIs) [5, 6], EGFR-TKIs have been considered as the standard first-line therapy of EGFR mutation-positive advanced NSCLC [2, 7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.